Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
Read MSF's submission to the United States Trade Representative on the 2014 Special 301 review process, which affects accessibility of medicines and important diagnostic tools, highlighting in particular the effects of the Special 301 review for India.
Last updated 2 April 2014
USTR’s proposal for the Intellectual Property Chapter of the Trans-Pacific Partnership (TPP) will endanger access to medicines for all
18 March, 2014, Geneva -"On February 12, 2014, MSF, Oxfam, Public Citizen and others released a joint statement expressing concerns about the public health implications of the United States Trade Representative's latest proposals for the Trans-Pacific Partnership agreement, which threatens access to affordable medicines throughout the whole Asia-Pacific region."
4 March, 2014, Geneva - French pharmaceutical company Sanofi Pasteur has announced a deal with UNICEF to supply significant quantities of its inactivated polio vaccine (IPV) to countries on a tiered price basis as part of a global plan to eradicate polio. Tiered pricing is a strategy long used by pharmaceutical companies to maximize profits by segmenting developing countries into different price bands based on socio-economic status.
Last updated 4 March 2014
MSF response to European Parliament proposals of EU enforcement of European trademarks on goods in transit
Last updated 24 February 2014
MSF response to the licensing deal announced between US pharmaceutical firm Merck Sharp & Dohme and Cipla for the HIV medicine raltegravir
Raltegravir is an important HIV medicine currently used to treat patients who have failed both first- and second-line antiretroviral treatment. It was among the first HIV medicines to be patented in India, and with the patent not expiring before 2022, open generic competition on this medicine is blocked. Middle-income countries currently pay more than US$5,000 per patient per year for raltegravir, with MSF paying over $1,700 per patient per year for raltegravir in our treatment programmes in India.
Last updated 21 February 2014
MSF oral testimony to the United States International Trade Commission public hearing on Trade Investment and Industrial Policies in India: Effects on the U.S. Economy
14 February, 2014 - Good afternoon. My name is Rohit Malpani and I am the Director of Policy and Analysis at the Access Campaign of Doctors Without Borders/ Médecins Sans Frontières - also known by our French acronym, MSF.
Last updated 17 February 2014
In a Hindu BusinessLine article dated 3 February 2014, Gilead indicated it would charge $2,000 per 24 week treatment course for the hepatitis C drug sofosbuvir that was recently approved by both the US Food and Drug Administration and the European Medicines Agency. Gilead also indicated it is in negotiations with several generics manufacturers based in India to sign voluntary licenses that would allow for sales of sofosbuvir in only 60 developing countries.
Last updated 7 February 2014
Last updated 31 January 2014
28 January 2014WIPO Standing Committee on the Law of Patents – Twentieth Session
Last updated 29 January 2014
24 January 2014134th WHO Executive Board meeting – Agenda item 10.6: Antimicrobial resistance In contexts ranging from child nutritional centres in Niger to adult trauma sites in Syria, Médecins Sans Frontières sees first-hand the emergence of high rates of resistant bacteria, including ESBLs and MRSA.
Last updated 24 January 2014